Perceptive Advisors’s United Therapeutics UTHR Stock Holding History

Perceptive Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-94,064	Closed	-$20.3M	–	150
2021 Q4	$20.3M	Sell	94,064 -47,636	-34%	-$9.35M	0.31%	67
2021 Q3	$26.2M	Sell	141,700 -475,102	-77%	-$93.6M	0.38%	62
2021 Q2	$111M	Buy	616,802 +441,802	+252%	+$84.1M	1.44%	20
2021 Q1	$29.3M	Buy	+175,000	New	+$29.2M	0.37%	59
2017 Q1	–	Sell	-4,753	Closed	-$682K	–	200
2016 Q4	$682K	Hold	4,753	–	–	0.05%	102
2016 Q3	$561K	Hold	4,753	–	–	0.04%	114
2016 Q2	$503K	Sell	4,753 -15,247	-76%	-$1.7M	0.03%	120
2016 Q1	$2.23M	Buy	+20,000	New	+$2.53M	0.2%	85
2015 Q2	–	Sell	-1,481	Closed	-$255K	–	187
2015 Q1	$255K	Buy	+1,481	New	+$226K	0.02%	128
2014 Q1	–	Sell	-7,000	Closed	-$792K	–	142
2013 Q4	$792K	Buy	+7,000	New	+$631K	0.1%	71

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Perceptive Advisors's UTHR Position: Q1 2022 in Review

Perceptive Advisors sold out of United Therapeutics (UTHR) in Q1 2022, closing a stake of 94,064 shares — an estimated $20.3M sold.

Perceptive Advisors first reported a position in UTHR in Q4 2013 and held it in 10 quarters. The position peaked at $111M in Q2 2021. 427 funds tracked by Wall St. Rank hold UTHR as of Q1 2022.

Perceptive Advisors reported no remaining United Therapeutics position as of Q1 2022 after selling out during the quarter.
Perceptive Advisors sold 94,064 United Therapeutics shares in Q1 2022, an estimated $20.3M.
Perceptive Advisors first reported a position in United Therapeutics in Q4 2013 and held it in 10 quarters.
Perceptive Advisors's United Therapeutics position peaked at $111M in Q2 2021.
427 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.